U.S. flag

An official website of the United States government

NM_000391.4(TPP1):c.857A>G (p.Asn286Ser) AND Neuronal ceroid lipofuscinosis 2

Germline classification:
Likely pathogenic (3 submissions)
Last evaluated:
May 15, 2017
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000002767.10

Allele description [Variation Report for NM_000391.4(TPP1):c.857A>G (p.Asn286Ser)]

NM_000391.4(TPP1):c.857A>G (p.Asn286Ser)

Gene:
TPP1:tripeptidyl peptidase 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
11p15.4
Genomic location:
Preferred name:
NM_000391.4(TPP1):c.857A>G (p.Asn286Ser)
HGVS:
  • NC_000011.10:g.6616690T>C
  • NG_008653.1:g.7772A>G
  • NM_000391.4:c.857A>GMANE SELECT
  • NP_000382.3:p.Asn286Ser
  • LRG_830t1:c.857A>G
  • LRG_830:g.7772A>G
  • LRG_830p1:p.Asn286Ser
  • NC_000011.9:g.6637921T>C
  • NM_000391.3:c.857A>G
  • O14773:p.Asn286Ser
Protein change:
N286S; ASN286SER
Links:
UniProtKB: O14773#VAR_016796; UniProtKB/Swiss-Prot: VAR_016796; OMIM: 607998.0008; dbSNP: rs119455958
NCBI 1000 Genomes Browser:
rs119455958
Molecular consequence:
  • NM_000391.4:c.857A>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Neuronal ceroid lipofuscinosis 2
Synonyms:
JANSKY-BIELSCHOWSKY DISEASE NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE; TPP1-Related Neuronal Ceroid-Lipofuscinosis
Identifiers:
MONDO: MONDO:0008769; MedGen: C1876161; Orphanet: 168491; Orphanet: 228349; Orphanet: 79264; OMIM: 204500

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000022925OMIM
no assertion criteria provided
Pathogenic
(Apr 1, 2004)
germlineliterature only

PubMed (2)
[See all records that cite these PMIDs]

SCV000091201UniProtKB/Swiss-Prot
no classification provided
not providednot providednot provided

PubMed (1)
[See all records that cite this PMID]

SCV000791297Counsyl
criteria provided, single submitter

(Counsyl Autosomal Recessive and X-Linked Classification Criteria (2018))
Likely pathogenic
(May 15, 2017)
unknownclinical testing

PubMed (5)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenot providednot providednot providednot providednot providednot providedliterature only
not providednot providednot providednot providednot providednot provided1not providedliterature only
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes.

Steinfeld R, Steinke HB, Isbrandt D, Kohlschütter A, Gärtner J.

Hum Mol Genet. 2004 Oct 15;13(20):2483-91. Epub 2004 Aug 18.

PubMed [citation]
PMID:
15317752

Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity.

Tsiakas K, Steinfeld R, Storch S, Ezaki J, Lukacs Z, Kominami E, Kohlschütter A, Ullrich K, Braulke T.

Glycobiology. 2004 Apr;14(4):1C-5C. Epub 2004 Jan 21.

PubMed [citation]
PMID:
14736728
See all PubMed Citations (5)

Details of each submission

From OMIM, SCV000022925.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedliterature only PubMed (2)

Description

In 2 unrelated female patients of Kurdish ethnicity with late infantile neuronal ceroid lipofuscinosis-2 (CLN2; 204500), Steinfeld et al. (2002) identified a homozygous A-to-G transition at nucleotide 857 in exon 7 of the TPP1 gene. The mutation resulted in an asn286-to-ser (N286S) substitution that altered 1 of 5 N-glycosylation sites in the TPP1 protein. Both patients had a more protracted clinical course compared with patients with typical disease progression.

By transient transfection analysis in human embryonic kidney cells, Tsiakas et al. (2004) found that TPP1 containing the N286S mutation was synthesized and sorted in the Golgi like wildtype TPP1, but it was expressed at a lower level and was enzymatically inactive. TPP1 with the N286 mutation had an apparent molecular mass 2 kD lower than that of wildtype TPP1, whereas deglycosylation of mutant and wildtype TPP1 led to proteins of the same size. Tsiakas et al. (2004) concluded that TPP1 with the N286S mutation lacks 1 oligosaccharide chain, resulting in enzymatic inactivation and possibly prelysosomal protein degradation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenot providednot providednot providednot providednot providednot providednot providednot provided

From UniProtKB/Swiss-Prot, SCV000091201.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providednot provided PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1not providednot provided1not providednot providednot providednot providednot providednot provided

From Counsyl, SCV000791297.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (5)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024